Scientists hunt for clues to why immunotherapy fails in most patients

This study looked at 135 people with advanced lung cancer, lymphoma, or other tumors treated with immunotherapy drugs called checkpoint inhibitors. Researchers collected blood and tumor samples over time to measure immune cells and molecules that might predict whether the treatment works. The goal was to better understand why some patients respond and others do not, but this was an observational study, not a treatment trial.